Enhanced local tumour control after single or fractionated radiation treatment using the hypoxic cell radiosensitizer doranidazole

Radiotherapy and Oncology

Volumn 87, Issue 3, 2008, Pages 331-338

  Murata, Rumi ^a   Tsujitani, Michihiko ^b   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b POLA PHARMA INC   (Japan)

Author keywords

C3H mouse mammary carcinoma; Doranidazole; Radiation sensitizer; Skin damage

Indexed keywords

ANTINEOPLASTIC AGENT; DORANIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; C3H MOUSE; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SIZE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION;

ANIMALS; CELL HYPOXIA; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; IMIDAZOLES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; NEOPLASM TRANSPLANTATION; RADIATION-SENSITIZING AGENTS; SKIN;

EID: 46549085948     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.03.002     Document Type: Article

References (44)

1. Moulder J.E., and Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int J Radiat Oncol Biol Phys 10 (1984) 695-712
2. Vaupel P., Kallinowski F., and Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49 (1989) 6449-6465
3. Hoeckel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56 (1996) 4509-4515
4. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
5. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., and Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38 (1997) 285-289
6. Horsman M.R., Lindegaard J.C., Grau C., Nordsmark M., and Overgaard J. Dose response modifiers in radiation therapy. In: Gunderson L.L., and Tepper J.E. (Eds). Clinical radiation oncology (2007), Churchill Livingstone, New York 59-73
7. Overgaard J., Hansen H.S., Andersen A.P., Hjelm-Hansen M., Jorgensen K., Sandberg E., et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx. Final report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16 (1989) 1065-1068
8. Overgaard J., Hansen H.S., Overgaard M., Bastholt L., Berthelsen A., Specht L., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
9. Overgaard J., Overgaard M., Nielsen O.S., Pedersen A.K., and Timothy A.R. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer 46 (1982) 904-911
10. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 25 (2007) 4066-4074
11. Shibamoto Y., Sakano K., Kimura R., Nishidai T., Nishimoto S.I., Ono K., et al. Radiosensitization in vitro and in vivo by 3-nitrotriazoles. Int J Radiat Oncol Biol Phys 12 (1986) 1063-1066
12. Dobrowsky W., Huigol N.G., Jayatilake R.S., Kizilbash N.I.A., Okkan S., Kagiya V.T., et al. AK-2123 (sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomized trial. Radiother Oncol 82 (2007) 24-29
13. Murayama C., Suzuki A., Sato C., Tanabe Y., Shoji T., Miyata Y., et al. Radiosensitization by a new potent nucleoside analog: 1-(1′,3′,4′-trihydroxy-2′-butoxy)methyl-2-nitroimidazole(RP-343). Int J Radiat Oncol Biol Phys 26 (1993) 433-443
14. Oya N., Shibamoto Y., Sasai K., Shibata T., Murata R., Takagi T., et al. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol Phys 33 (1995) 119-127
15. Shibamoto Y., Kubota T., Kishii K., and Tsujitani M. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol 56 (2000) 265-270
16. Kuno Y., and Shinomiya N. PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction. Apoptosis 5 (2000) 69-77
17. Aoki M., Furusawa Y., Shibamoto Y., Kobayashi A., and Tsujitani M. Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells. J Radiat Res 43 (2002) 161-166
18. Mizumoto K., Qian L.W., Zhang L., Nagai E., Kura S., and Tanaka M. A nitroimidazole derivative, PR-350, enhances the killing of pancreatic cancer cells exposed to high-dose irradiation under hypoxia. J Radiat Res 43 (2002) 43-51
19. Yahiro T., Masui S., Kubota N., Yamada K., Kobayashi A., and Kishii K. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo. J Radiat Res 46 (2005) 363-372
20. Suzuki Y., Hasegawa M., Hayakawa K., Mitsuhashi N., and Niibe H. In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer. Anticancer Res 19 (1999) 3993-4000
21. Matsuoka H., Shibamoto Y., Kubota T., Tsujitani M., and Majima T. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas. Oncol Rep 7 (2000) 23-26
22. Nemoto K., Shibamoto Y., Ohmagari J., Baba Y., Ebe K., Ariga H., et al. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anticancer Drugs 12 (2001) 1-6
23. Sunamura M., Karasawa K., Okamoto A., Ogata Y., Nemoto K., Hosotani R., et al. PR-350 study group. Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas 28 (2004) 330-334
24. Karasawa K., Sunamura M., Okamoto A., Nemoto K., Matsuno S., Nishimura Y., et al. Efficacy of novel hypoxic cell sensitizer doranidazole in the treatment of locally advanced pancreatic cancer - long-term results of a placebo-controlled randomised study. Radiother Oncol 87 (2008) 326-330
25. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 6 (1980) 1507-1517
26. Horsman M.R., Chaplin D.J., and Overgaard J. Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumour cells. Cancer Res 50 (1990) 7430-7436
27. Raleigh J.A., Chou S.C., Arteel G.E., and Horsman M.R. Comparisons among pimonidazole binding, oxygen electrode measurements and radiation response in C3H mouse tumors. Radiat Res 151 (1999) 580-589
28. Horsman M.R., Khalil A.A., Siemann D.W., Grau C., Hill S.A., Lynch E.M., et al. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. Int J Radiat Oncol Biol Phys 29 (1994) 439-442
29. Grau C., Horsman M.R., and Overgaard J. Improving the radiation response in a C3H mouse mammary carcinoma by normobaric oxygen or carbogen breathing. Int J Radiat Oncol Biol Phys 22 (1992) 415-419
30. Horsman M.R., and Overgaard J. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen. Radiother Oncol 70 (2004) 301-309
31. Hendry J.H., and Sutton M.L. Care with radiosensitizers. Br J Radiol 51 (1978) 927-928
32. Hendry J.H. Quantitation of the radiotherapeutic importance of naturally-hypoxic normal tissues from collated experiments with rodents using single doses. Int J Radiat Oncol Biol Phys 5 (1979) 971-976
33. Timothy AR, Overgaard J. In-vivo radiosensitisation by nimorazole and hyperthermia. In: Overgaard J, editor. Hyperthermic oncology 1984, volume 1. Summary papers. London: Taylor and Francis; 1984. p. 309-10.
34. Mao H.S., Grau C., and Overgaard J. Interaction of misonidazole, hyperthermia, and irradiation in a C3H mammary carcinoma and its surrounding skin in vivo. Int J Radiat Oncol Biol Phys 22 (1991) 115-122
35. Denekamp J. Testing of hypoxic cell radiosensitizers in vivo. Cancer Clin Trials 3 (1980) 139-148
36. Stewart F.A., Denekamp J., and Randhawa V.S. Skin sensitisation by misonidazole: a demonstration of uniform mild hypoxia. Br J Cancer 45 (1982) 869-877
37. Horsman M.R., Siemann D.W., Chaplin D.J., and Overgaard J. Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing. Radiother Oncol 45 (1997) 167-174
38. Murata R., Siemann D.W., Overgaard J., and Horsman M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol 60 (2001) 155-161
39. Hill R.P. Sensitizers and radiation dose fractionation: results and interpretations. Int J Radiat Oncol Biol Phys 12 (1986) 1049-1054
40. Horsman M.R., Grau C., and Overgaard J. Reoxygenation in a C3H mouse mammary carcinoma: the importance of chronic rather than acute hypoxia. Acta Oncol 34 (1995) 325-328
41. Nishimura Y., Nakagawa K., Takeda K., Tanaka M., Segawa Y., Tsujino K., et al. Phase I/II trial of sequential chemotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung cancer (WJTOG-0002). Int J Radiat Oncol Biol Phys 69 (2007) 786-792
42. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6 (1994) 509-518
43. Workman P. Pharmacokinetics of hypoxic cell radiosensitizers: a review. In: Brady L.W. (Ed). Radiation sensitizers: their use in the clinical management of cancer (1980), Masson, New York 192-206
44. Lee D.-J., Cosmatos D., Marcial V.A., Fu K.K., Rotman M., Cooper J.S., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole (SR-2508) with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32 (1995) 567-576